A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 316
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : AA
Long Form : aristolochic acid
No. Year Title Co-occurring Abbreviation
2020 Hirsutella sinensis inhibits NLRP3 inflammasome activation to block aristolochic acid-induced renal tubular epithelial cell transdifferentiation. AAN, HS
2019 Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway. ERK, MAPK, MCA, UTUC
2019 Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. UCB
2019 Assessment of nephrotoxicity of herbal medicine containing aristolochic acid in mice. HM, NGAL, TUNEL
2019 Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid. ---
2019 Bardoxolone ameliorates TGF-beta1-associated renal fibrosis through Nrf2/Smad7 elevation. alpha-SMA, BARD, ECM, Keap1, Smurf1, TbetaR1, TGF-beta
2019 Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models. AAI, pHKC
2019 Developed a novel sensor based on fluorescent graft conjugated polymer for the determination of aristolochic acid in traditional Chinese medicine. LOD
2019 Effects of Human Placental Amnion Derived Mesenchymal Stem Cells on Proliferation and Apoptosis Mechanisms in Chronic Kidney Disease in the Rat. CKF, hAMSCs, MSCs
10  2019 Electromembrane extraction of aristolochic acids: New insights in separation of bioactive ingredients of traditional Chinese medicines. ALA, EME, RA, TCMs
11  2019 Exposure to aristolochic acid I compromises the maturational competency of porcine oocytes via oxidative stress-induced DNA damage. ---
12  2019 Genome-wide somatic mutation analysis via Hawk-Seq™ reveals mutation profiles associated with chemical mutagens. BP, DEN, ENU, MNU
13  2019 Herbal Medicine Containing Aristolochic Acid and the Risk of Primary Liver Cancer in Patients with Hepatitis C Virus Infection. CI, HCV, HM, PLC
14  2019 Inhibition of 4E-BP1 phosphorylation promotes tubular cell escaping from G2/M arrest and ameliorates kidney fibrosis. ---
15  2019 Mitochondrial dysfunction is involved in aristolochic acid I-induced apoptosis in renal proximaltubular epithelialcells. AAI, AAN, ATP, MMP, mtDNA, NRK-52E, PTEC, ROS
16  2019 Protective Effects of Melatonin Against Aristolochic Acid-Induced Nephropathy in Mice. ---
17  2019 Protective role of relaxin in a mouse model of aristolochic acid nephropathy. AAN, RLX
18  2019 Recognition of the toxicity of aristolochic acid. AAN, HCC
19  2019 Reply to HEP-19-1824. AAI, HCC
20  2019 The Disturbance of Hepatic and Serous Lipids in Aristolochic Acid Iota Induced Rats for Hepatotoxicity Using Lipidomics Approach. AAI, AAN
21  2019 The Impact of p53 on Aristolochic Acid I-Induced Gene Expression In Vivo. AAI, BW
22  2019 The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro. BW, GC-MS, MEFs, NMR
23  2019 The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers. AAI, HCC, PTEN
24  2018 A comparison between the effects of ochratoxin A and aristolochic acid on the inflammation and oxidative stress in the liver and kidney of weanling piglets. CAT, GPx, IFN, IL, OTA, SOD, TNF
25  2018 Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. BR, CSS, CUTR, UTUC
26  2018 Carcinogens that induce the A:T > T:A nucleotide substitutions in the genome. HCC
27  2018 Cooking methods employing natural anti-oxidant food additives effectively reduced concentration of nephrotoxic and carcinogenic aristolochic acids in contaminated food grains. ---
28  2018 Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. CKD, CTGF, HK, Smad, TAZ, YAP
29  2018 Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis. BEL, MAFP, PLA2
30  2018 Glucofucogalactan, a heterogeneous low-sulfated polysaccharide from Saccharina japonica and its bioactivity. ---
31  2018 Glycine N-methyltransferase inhibits aristolochic acid nephropathy by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes. AAI, GNMT
32  2018 Human Liver Stem Cell-Derived Extracellular Vesicles Prevent Aristolochic Acid-Induced Kidney Fibrosis. CKD, HLSC-EVs, miRNAs
33  2018 Inhibition of phospholipases influences the metabolism of wound-induced benzylisoquinoline alkaloids in Papaver somniferum L. BIAs, FIPI, PLD
34  2018 Proteomics analysis of altered proteins in kidney of mice with aristolochic acid nephropathy using the fluorogenic derivatization-liquid chromatography-tandem mass spectrometry method. AAN, GPR87, TSP1
35  2018 Update of aristolochic acid nephropathy in Korea. AAN, ESRD
36  2018 Vitamin E (alpha‑tocopherol) ameliorates aristolochic acid‑induced renal tubular epithelial cell death by attenuating oxidative stress and caspase‑3 activation. ---
37  2017 A systematic review of the possible carcinogenic role of the aristolochic acid. UTUC
38  2017 An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. AAN
39  2017 Aristolochic acid and its derivatives as inhibitors of snake venom L-amino acid oxidase. LAAO, ROS
40  2017 Aristolochic Acid-Induced Autophagy Promotes Epithelial-to-Myofibroblast Transition in Human Renal Proximal Tubule Epithelial Cells. EMT
41  2017 DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer. AAI, AAN, BEN, UUC
42  2017 Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? SGLT2
43  2017 Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. HR, IVR, RNU, UTUC
44  2017 Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. 3-NBA, AAI, AAII, AAN, BEN, SULT1A1, WT
45  2017 Prescribed Renoprotective Chinese Herbal Medicines Were Associated with a Lower Risk of All-Cause and Disease-Specific Mortality among Patients with Chronic Kidney Disease: A Population-Based Follow-Up Study in Taiwan. aHR, CHMs, CKD, RPCHM
46  2017 Protective effects of cyclic helix B peptide on aristolochic acid induced acute kidney injury. CHBP
47  2017 Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy. AKI, CKD, L-Arg, NO
48  2017 The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-beta1. AAN, BZM, CKD, MM
49  2017 TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis. AAN, IHC, UC
50  2017 Urinary Time- or Dose-Dependent Metabolic Biomarkers of Aristolochic Acid-Induced Nephrotoxicity in Rats. BUN, GC-MS
51  2016 Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis. miRNA
52  2016 Aristolochic acid exposure in Romania and implications for renal cell carcinoma. AAN, AL, RCC, UUTC
53  2016 Aristolochic Acid I Causes Testis Toxicity by Inhibiting Akt and ERK1/2 Phosphorylation. AAI, Bcl-2
54  2016 Aristolochic Acid in the Etiology of Renal Cell Carcinoma. AL, ccRCC
55  2016 Balkan endemic nephropathy: an update on its aetiology. BEN, UUC
56  2016 Evaluation for a mutagenicity of aristolochic acid by Pig-a and PIGRET assays in rats. IWGT, PIG-A
57  2016 Evaluation of nephrotoxic effects of aristolochic acid on zebrafish (Danio rerio) larvae. ---
58  2016 Expression of Renal Aquaporins in Aristolochic Acid I and Aristolactam I-Induced Nephrotoxicity. AL-I, AQPs
59  2016 Hirsutella sinensis Attenuates Aristolochic Acid-Induced Renal Tubular Epithelial-Mesenchymal Transition by Inhibiting TGF-beta1 and Snail Expression. alpha-SMA, Ccr, EMT, HS, TGF-beta1
60  2016 Inhibition of Macrophage Migration Inhibitory Factor Protects against Inflammation and Matrix Deposition in Kidney Tissues after Injury. MIF, TECs
61  2016 Interplay between chronic kidney disease (CKD) and upper tract urothelial carcinomas (UUC): foe or friend? CKD
62  2016 Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy. AAN
63  2016 Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact? BNe, HNPCC, LS, UTUC
64  2016 New in vitro insights on a cell death pathway induced by magnolol and honokiol in aristolochic acid tubulotoxicity. ---
65  2016 Omeprazole Alleviates Aristolochia manshuriensis Kom-Induced Acute Nephrotoxicity. AMK, OM
66  2016 Patients with urothelial carcinoma have poor renal outcome regardless of whether they receive nephrouretectomy. BUC, CI, HRs, UC, UTUC
67  2016 Preparation of a nitric oxide imaging agent from gelatin derivative micelles. LPS, NO
68  2016 Protective effect of nitric oxide in aristolochic acid-induced toxic acute kidney injury: an old friend with new assets. L-Arg, NO, NOX2
69  2016 Reduced rat plasma lysophosphatidylglycerol or lysophosphatidic acid level as a biomarker of aristolochic acid-induced renal and adipose dysfunctions. LPA, LPG, LPL
70  2016 Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. AL-I-NOH, SULT
71  2016 Transforming growth factor-beta1 stimulates hedgehog signaling to promote epithelial-mesenchymal transition after kidney injury. ECM, EMT, TECs, TGF
72  2015 Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. AAN, CYP1A1, ESRD
73  2015 Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. AAN, ESRD
74  2015 Comparison of DNA and RNA Adduct Formation: Significantly Higher Levels of RNA than DNA Modifications in the Internal Organs of Aristolochic Acid-Dosed Rats. ---
75  2015 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. CKD, UUC
76  2015 Human bone morphogenetic protein-7 does not counteract aristolochic acid-induced renal toxicity. rhBMP
77  2015 Impairment of the Cellular Distribution and Stability of the Erythropoietin Receptor Through the Direct Targeting of Aristolochic Acid. EpoR
78  2015 Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid. HCA, IPA, miRNAs, PCA
79  2015 Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. LC-WES
80  2015 Mass Spectrometric and Spectrofluorometric Studies of the Interaction of Aristolochic Acids with Proteins. AAI, AAII, BSA, MS
81  2015 Mutation signatures implicate aristolochic acid in bladder cancer development. ---
82  2015 Nephroprotective role of resveratrol and ursolic Acid in aristolochic Acid intoxicated zebrafish. RESV, UA
83  2015 New Approaches for Biomonitoring Exposure to the Human Carcinogen Aristolochic Acid. AAN, AL, FFPE
84  2015 Prediction and Characterisation of the System Effects of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological Mechanisms. PPI
85  2015 Quantification of aristolochic acid-RNA adducts in the urine of aristolochic acid-treated rats by liquid chromatography-tandem mass spectrometry. BEN
86  2015 Reduced kidney levels of lysophosphatidic acids in rats after chronic administration of aristolochic acid: Its possible protective role in renal fibrosis. LPA
87  2015 Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. AAN, EN, RCC
88  2015 Revealing a Pre-neoplastic Renal Tubular Lesion by p-S6 Protein Immunohistochemistry after Rat Exposure to Aristolochic Acid. ---
89  2015 Substitution between Aristolochia and Bryonia genus in North-Eastern Morocco: toxicological implications. ---
90  2015 The genome as a record of environmental exposure. BaP, UV
91  2015 The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats. BEN, OTA, UUC
92  2015 Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks. ---
93  2015 Upper urinary tract disease: what we know today and unmet needs. AC, RNU, UCB, UTUC
94  2015 Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. ---
95  2015 Vitamin C attenuates the toxic effect of aristolochic acid on renal tubular cells via decreasing oxidative stress‑mediated cell death pathways. ---
96  2015 [Application of ultra high performance liquid chromatography-mass spectrometry to metabolomics study of drug-induced hepatotoxicity]. UPLC-MS
97  2015 [Exploring the Correlation between Pi and Shen from the Excretion of AA-I and Expressions of Or- ganic Anion Transporting Polypeptide 2al and 2 b1 in Pi Deficiency Model Rats]. OATP, PDS, RT- PCR, SD
98  2014 Acute kidney injury induced by aristolochic acid in patients with primary glomerular nephritis. AAN, CGN, SCr
99  2014 An exploratory evaluation of the utility of transcriptional and urinary kidney injury biomarkers for the prediction of aristolochic acid-induced renal injury in male rats. ---
100  2014 Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. AAI, AAN, AKI, BARD, BUN, HO-1, i.p, Keap1, NQO1, Nrf2, SCr